96 related articles for article (PubMed ID: 2875821)
1. Pharmacokinetics and effects of intravenous infusion of somatostatin in normal subjects--a two-compartment open model.
Ho LT; Chen RL; Chou TY; Fong JC; Wang PS; Chou CK
Clin Physiol Biochem; 1986; 4(4):257-67. PubMed ID: 2875821
[TBL] [Abstract][Full Text] [Related]
2. A-Cell and gut glucagon in normal and depancreatized dogs. Inhibition by somatostatin and insulin.
Matsuyama T; Wider MD; Tanaka R; Shima K; Tarui S; Nishikawa M; Foà PP
Diabete Metab; 1979 Jun; 5(2):141-7. PubMed ID: 478084
[TBL] [Abstract][Full Text] [Related]
3. Possible mechanisms and significance of the neonatal surge in glucagon secretion: studies in newborn lambs.
Grajwer LA; Sperling MA; Sack J; Fisher DA
Pediatr Res; 1977 Jul; 11(7):833-6. PubMed ID: 876705
[TBL] [Abstract][Full Text] [Related]
4. Metabolic effects of graded glucagon infusions in man: inhibition of glucagon, insulin, and somatostatin response to arginine.
Pontiroli AE; Perfetti MG; Andreotti AC; Fattor B; Monti LD; Pozza G
Metabolism; 1993 Oct; 42(10):1242-8. PubMed ID: 8105365
[TBL] [Abstract][Full Text] [Related]
5. Response of plasma somatostatin-like immunoreactivity to the administration of alloxan in dogs.
Schusdziarra V; Harris V; Unger R
Horm Metab Res; 1979 Aug; 11(8):457-9. PubMed ID: 499995
[TBL] [Abstract][Full Text] [Related]
6. Low-dose infusion of somatostatin in man--no effect upon intestinal calcium absorption but a fall in blood insulin.
Rümenapf G; Hanisch E; Schwille PO
Exp Clin Endocrinol; 1986 Aug; 87(3):306-12. PubMed ID: 2877894
[TBL] [Abstract][Full Text] [Related]
7. Effects of cyclic somatostatin on insulin, C-peptide and immunoreactive glucagon response to oral glucose loading in obese patients.
Papalia D; Trovato G; Maugeri D; Tribulato A; Lunetta M
Int J Obes; 1982; 6(1):113-20. PubMed ID: 6121763
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of somatostatin in regulating pancreatic splenic lobe hormone secretion following 99% pancreatectomy in adult chickens.
Cieslak SR; Hazelwood RL
Gen Comp Endocrinol; 1986 Aug; 63(2):284-94. PubMed ID: 2877920
[TBL] [Abstract][Full Text] [Related]
9. Effect of somatostatin in the Syrian hamster bearing a transplantable islet-cell tumor.
Luyckx AS; Lefebvre PJ
Horm Metab Res; 1978 Mar; 10(2):105-10. PubMed ID: 206496
[TBL] [Abstract][Full Text] [Related]
10. Plasma somatostatin in normal subjects and in various diseases: increased levels in somatostatin-producing tumors.
Saito H; Saito S
Horm Metab Res; 1982 Feb; 14(2):71-6. PubMed ID: 6121747
[TBL] [Abstract][Full Text] [Related]
11. Establishment of a radioimmunoassay of somatostatin in human plasma and in rat hypothalamus.
Ho LT; Lam HC; Wang JT; Tang KT; Perng JC; Liu YF; Chen RL
Chin J Physiol; 1986; 29(2):91-103. PubMed ID: 2884084
[TBL] [Abstract][Full Text] [Related]
12. Effect of a 12-hour subcutaneous infusion of somatostatin-14 on blood glucose, insulin and glucagon levels in healthy subjects and insulin dependent diabetics.
Villaume C; Beck B; Kolopp M; Toussain P; Debry G
Biomed Pharmacother; 1986; 40(2):61-4. PubMed ID: 2875745
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin infusion inhibits glucose production in burn patients.
Wolfe RR; Burke JF
Circ Shock; 1982; 9(5):521-7. PubMed ID: 6129073
[TBL] [Abstract][Full Text] [Related]
14. Reversal of somatostatin inhibition of insulin and glucagon secretion.
Bhathena SJ; Perrino PV; Voyles NR; Smith SS; Wilkins SD; Coy DH; Schally AV; Recant L
Diabetes; 1976 Nov; 25(11):1031-40. PubMed ID: 992224
[TBL] [Abstract][Full Text] [Related]
15. Physiologic modeling of the intravenous glucose tolerance test in type 2 diabetes: a new approach to the insulin compartment.
Ward GM; Walters JM; Barton J; Alford FP; Boston RC
Metabolism; 2001 May; 50(5):512-9. PubMed ID: 11319711
[TBL] [Abstract][Full Text] [Related]
16. Effects of glucocorticoids on hepatic sensitivity to insulin and glucagon in man.
Dirlewanger M; Schneiter PH; Paquot N; Jequier E; Rey V; Tappy L
Clin Nutr; 2000 Feb; 19(1):29-34. PubMed ID: 10700531
[TBL] [Abstract][Full Text] [Related]
17. Hormonal and metabolic effects of near physiological increase of plasma immunoreactive somatostatin 14.
Souquet JC; Rambliere R; Riou JP; Beylot M; Cohen R; Mornex R; Chayvialle JA
J Clin Endocrinol Metab; 1983 May; 56(5):1076-9. PubMed ID: 6131904
[TBL] [Abstract][Full Text] [Related]
18. Effect of guar intake on plasma somatostatin-like immunoreactivity in diabetic patients.
Shimoyama R; Uehara S; Itagaki Y; Izumiyama S; Hirayama A
Hokkaido Igaku Zasshi; 1982 Nov; 57(6):727-33. PubMed ID: 6134660
[TBL] [Abstract][Full Text] [Related]
19. Half-life of somatostatin-like immunoreactivity in canine plasma.
Schusdziarra V; Harris V; Unger RH
Endocrinology; 1979 Jan; 104(1):109-10. PubMed ID: 446338
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of motilin in man.
Mitznegg P; Bloom SR; Domschke W; Domschke S; Wuensch E; Demling L
Gastroenterology; 1977 Mar; 72(3):413-6. PubMed ID: 832789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
